Nuvation Bio Inc. (NUVB) Stock
NUVB Key Statistics
About Nuvation Bio Inc.
Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6. The company's development pipeline further encompasses NUV-868, an orally administered, selective small molecule BET inhibitor that epigenetically influences proteins critical for tumor proliferation and cellular differentiation; NUV-569, a unique oral small molecule targeting the Wee1 kinase to facilitate DNA damage repair; and NUV-1182, an antagonist of adenosine receptors. Additionally, Nuvation Bio is progressing a sophisticated drug-drug conjugate (DDC) platform, engineered to deliver a poly ADP ribose polymerase (PARP) inhibitor in conjunction with existing anti-cancer warheads, particularly for the treatment of ER-positive breast and ovarian cancers. Established in 2018, the firm was initially named RePharmation Inc. before rebranding as Nuvation Bio Inc. in April 2019, and its central operations are based in New York, New York.
CEO: David T. Hung. Company website
NUVB — Frequently Asked Questions
What is the NUVB stock price today?
Nuvation Bio Inc. (NUVB) trades at $4.29, up 2.14% on the day, as of Nov 12, 2026 09:38 UTC.
What is Nuvation Bio Inc.'s market cap?
Nuvation Bio Inc. has a market capitalisation of $1.51B, calculated from the live NUVB share price and shares outstanding.
What is the P/E ratio of NUVB?
NUVB has no meaningful price-to-earnings ratio: Nuvation Bio Inc. lost $106.53 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Nuvation Bio Inc. make?
Nuvation Bio Inc. generated revenue of $201.73M over the trailing twelve months, which puts the stock at 7.47 times sales.
What is the 52-week range for NUVB?
NUVB has traded between $3.98 and $9.75 over the past 52 weeks, and the last price is 56.0% below that high.
Is Nuvation Bio Inc. profitable?
No. Nuvation Bio Inc. is loss-making, with a net margin of -67.38% over the trailing twelve months.
What is the analyst price target for NUVB?
Wall Street analysts rate NUVB Buy, with an average price target of $20.50, 377.9% above the current price.
What sector is Nuvation Bio Inc. in?
Nuvation Bio Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US.
Who is the CEO of Nuvation Bio Inc.?
David T. Hung is the chief executive of Nuvation Bio Inc., which employs 305 people.
Where can I track NUVB in real time?
QFI Terminal shows NUVB with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See NUVB live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open NUVB in Terminal See plans